British drugmaker AstraZeneca has appointed a new China head, replacing a former executive who has been detained by ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ...

Shares of AstraZeneca PLC AZN inched up 0.25% to £105.38 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.26% to 8,301.62.

Shares of AstraZeneca PLC AZN slid 1.78% to £105.12 Tuesday, on what proved to be an all-around dismal trading session for ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

When looking ahead to 2025, Cramer noted a significant lack of consensus about future rate cuts. He pointed to Fed funds ...

AstraZeneca has concluded its inaugural Week of Service, which ran from September 16 to 20, 2024, across the African cluster.

AstraZeneca (AZN) said the FDA has accepted its supplemental Biologics License Application for Imfinzi for Priority Review for the treatment of muscle-invasive bladder cancer.

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...